Regulation of insulin secretion in human pancreatic islets

Annual Review of Physiology

Volumn 75, Issue , 2013, Pages 155-179

  Rorsman, Patrik ^a   Braun, Matthias ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cell; Calcium; Exocytosis; Ion channels; Type 2 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CALCIUM CHANNEL T TYPE; CALCIUM ION; CHROMANOL 293B; GLUCOKINASE; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; HORMONE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL; ION CHANNEL; ISRADIPINE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LINOPIRDINE; N METHYL N [2 [METHYL(1 METHYL 1H BENZIMIDAZOL 2 YL)AMINO]ETHYL] 4 [(METHYLSULFONYL)AMINO]BENZENESULFONAMIDE; NEUROTRANSMITTER; NNC 553096; OMEGA AGATOXIN; POTASSIUM CHANNEL KCNQ1; PYRUVATE DEHYDROGENASE; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; SODIUM ION; TETRODOTOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ACTION POTENTIAL; BLOOD SAMPLING; CALCIUM SIGNALING; CELL MEMBRANE DEPOLARIZATION; DIABETES MELLITUS; DRUG INHIBITION; ELECTRIC POTENTIAL; EPIDEMIC; EXOCYTOSIS; FOOD INTAKE; GENE EXPRESSION; GENOTYPE ENVIRONMENT INTERACTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GRANULE CELL; HUMAN; INSULIN RELEASE; INTRACELLULAR MEMBRANE; MEAL; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PANCREAS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; RODENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ACTION POTENTIALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ION CHANNELS; ISLETS OF LANGERHANS;

EID: 84873670723     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-030212-183754     Document Type: Review

References (131)

1. Kahn SE. 2003. The relative contributions of insulin resistance and β-cell dysfunction to the pathophys-iology of type 2 diabetes. Diabetologia 46:3-19
2. Shaw JE, Sicree RA, Zimmet PZ. 2010. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87:4-14
3. Ashcroft FM, Rorsman P. 2012. Diabetes mellitus and the β cell: the last ten years. Cell 148:1160-71
4. Nolan CJ, Damm P, Prentki M. 2011. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378:169-81
5. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, et al. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343:230-38
6. Hellman B. 1959. The frequency distribution of the number and volume of the islets of Langerhans in man. I. Studies on non-diabetic adults. Acta Soc. Med. Ups. 64:432-60
7. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. 2006. The unique cytoar-chitecture of human pancreatic islets has implications for islet cell function. Proc. Natl. Acad. Sci. USA 103:2334-39
8. Jansson L, Hellerstrom C. 1986. Glucose-induced changes in pancreatic islet blood flow mediated by central nervous system. Am. J. Physiol. Endocrinol. Metab. 251:E644-47
9. Rodriguez-Diaz R, Abdulreda MH, Formoso AL, Gans I, Ricordi C, et al. 2011. Innervation patterns of autonomic axons in the human endocrine pancreas. Cell Metab. 14:45-54
10. Bosco D, Armanet M, Morel P, Niclauss N, Sgroi A, et al. 2010. Unique arrangement of α-and β-cells in human islets of Langerhans. Diabetes 59:1202-10
11. McCulloch LJ, van de Bunt M, Braun M, Frayn KN, Clark A, Gloyn AL. 2011. GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic βcells: implications for understanding genetic association signals at this locus. Mol. Genet. Metab. 104:648-53
12. De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, et al. 1995. Human and rat β cells differ in glucose transporter but not in glucokinase gene expression. J. Clin. Investig. 96:2489-95
13. Hoffer LJ, Forse RA. 1990. Protein metabolic effects of a prolonged fast and hypocaloric refeeding. Am. J. Physiol. Endocrinol. Metab. 258:E832-40
14. Frayn KN. 2010. Metabolic Regulation: A Human Perspective. Oxford, UK: Wiley-Blackwell. 384 pp.
15. Doliba NM, Qin W, Najafi H, Liu C, Buettger CW, et al. 2012. Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics. Am. J. Physiol. Endocrinol. Metab. 302:E87-102
16. Gloyn AL, Odili S, Zelent D, Buettger C, Castleden HA, et al. 2005. Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young. J. Biol. Chem. 280:14105-13
17. Schuit F, De Vos A, Farfari S, Moens K, Pipeleers D, et al. 1997. Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in β3 cells. J. Biol. Chem. 272:18572-79
18. Rebelato E, Abdulkader F, Curi R, Carpinelli AR. 2011. Control of the intracellular redox state by glucose participates in the insulin secretion mechanism. PLoS ONE 6:e24507
19. MacDonald MJ, Longacre MJ, Stoker SW, Kendrick M, Thonpho A, et al. 2011. Differences between human and rodent pancreatic islets: low pyruvate carboxylase, ATP citrate lyase, and pyruvate carboxy-lation and high glucose-stimulated acetoacetate in human pancreatic islets. J. Biol. Chem. 286:18383-96
20. Henquin JC, Dufrane D, Nenquin M. 2006. Nutrient control of insulin secretion in isolated normal human islets. Diabetes 55:3470-77
21. Hedeskov CJ. 1980. Mechanism of glucose-induced insulin secretion. Physiol. Rev. 60:442-509
22. Remedi MS, Agapova SE, Vyas AK, Hruz PW, Nichols CG. 2011. Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes. Diabetes 60:2515-22
23. Li DQ, Jing X, Salehi A, Collins SC, Hoppa MB, et al. 2009. Suppression of sulfonylurea-and glucose-induced insulin secretion in vitro and in vivo in mice lacking the chloride transport protein ClC-3. Cell Metab. 10:309-15
24. Ricordi C, Zeng YJ, Alejandro R, Tzakis A, Venkataramanan R, et al. 1991. In vivo effect of FK506 on human pancreatic islets. Transplantation 52:519-22
25. Rorsman P, Eliasson L, Kanno T, Zhang Q, Gopel S. 2011. Electrophysiology of pancreatic β3-cells in intact mouse islets of Langerhans. Prog. Biophys. Mol. Biol. 107:224-35
26. + channel in human pancreatic islet cells. Diabetes 38:422-27
27. Misler S, Barnett DW, Gillis KD, Pressel DM. 1992. Electrophysiology of stimulus-secretion coupling inhuman β3-cells. Diabetes 41:1221-28
28. +-currents in isolated mouse pancreatic β3-cells. FEBS Lett. 261:187-90
29. Ramracheya R, Ward C, Shigeto M, Walker JN, Amisten S, et al. 2010. Membrane potential-dependent inactivation of voltage-gated ion channels in tx-cells inhibits glucagon secretion from human islets. Diabetes 59:2198-208
30. + concentration oscillatory patterns in identified ex-and β3-cells within intact human islets of Langerhans. Diabetes 55:2463-69
31. + currents in human pancreatic islet β3-cells: evidence for roles in the generation of action potentials and insulin secretion. Pflug. Arch. 431:272-82
32. Braun M, Ramracheya R, Bengtsson M, Zhang Q, Karanauskaite J, et al. 2008. Voltage-gated ion channels in human pancreatic β3-cells: electrophysiological characterization and role in insulin secretion. Diabetes 57:1618-28
33. Kelly RP, Sutton R, Ashcroft FM. 1991. Voltage-activated calcium and potassium currents in human pancreatic β3-cells. J. Physiol. 443:175-92
34. Braun M. 2009. The txβ3 6 of ion channels in human islet cells. Islets 1:160-62
35. + channel CaV2. 3 (CACNA1E) are associated with type 2 diabetes and impaired insulin secretion. Diabetologia 50:2467-75
36. + currents in cultured mouse pancreatic β3-cells. Pflug. Arch. 411:429-35
37. Gopel S, Kanno T, Barg S, Galvanovskis J, Rorsman P. 1999. Voltage-gated and resting membrane currents recorded from β3-cells in intact mouse pancreatic islets. J. Physiol. 521(Pt. 3):717-28
38. Jacobson DA, Kuznetsov A, Lopez JP, Kash S, Ammala CE, Philipson LH. 2007. Kv2. 1 ablation alters glucose-induced islet electrical activity, enhancing insulin secretion. Cell Metab. 6:229-35
39. Herrington J. 2007. Gating modifier peptides as probes of pancreatic β-cell physiology. Toxicon 49:231-38
40. Dai XQ, Manning Fox JE, Chikvashvili D, Casimir M, Plummer G, et al. 2012. The voltage-dependent potassium channel subunit Kv2. 1 regulates insulin secretion from rodent and human islets independently of its electrical function. Diabetologia 55:1709-20
41. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, et al. 2008. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat. Genet. 40:1092-97
42. Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, et al. 2008. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat. Genet. 40:1098-102
43. + channels in firing and release. FASEB J. 14:2601-10
44. Braun M, Ramracheya R, Amisten S, Bengtsson M, Moritoh Y, et al. 2009. Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic δ cells. Diabetologia 52:1566-78
45. Dufer M, Gier B, Wolpers D, Krippeit-Drews P, Ruth P, Drews G. 2009. Enhanced glucose tolerance by SK4 channel inhibition in pancreatic β-cells. Diabetes 58:1835-43
46. + channels contributes to rhythmic firing of action potentials in mouse pancreatic β cells. J. Gen. Physiol. 114:759-70
47. 2+: experimental and theoretical studies. J. Gen. Physiol. 120:307-22
48. Jacobson DA, Mendez F, Thompson M, Torres J, Cochet O, Philipson LH. 2010. Calcium-activated and voltage-gated potassium channels of the pancreatic islet impart distinct and complementary roles during secretagogue induced electrical responses. J. Physiol. 588:3525-37
49. Colsoul B, Vennekens R, Nilius B. 2012. Transient receptor potential cation channels in pancreatic β cells. Rev. Physiol. Biochem. Pharmacol. 161:87-110
50. Gray E, Muller D, Squires PE, Asare-Anane H, Huang GC, et al. 2006. Activation of the extracellular calcium-sensing receptor initiates insulin secretion from human islets of Langerhans: involvement of protein kinases. J. Endocrinol. 190:703-10
51. Bandyopadhyay S, Tfelt-Hansen J, Chattopadhyay N. 2010. Diverse roles of extracellular calcium-sensing receptor in the central nervous system. J. Neurosci. Res. 88:2073-82
52. 2+-channel-evoked CICR regulates glucose-induced somatostatin secretion. Nat. Cell Biol. 9:453-60
53. Johnson JD, Kuang S, Misler S, Polonsky KS. 2004. Ryanodine receptors in human pancreatic β cells: localization and effects on insulin secretion. FASEB J. 18:878-80
54. Gilon P, Henquin JC. 2001. Mechanisms and physiological significance of the cholinergic control of pancreatic β-cell function. Endocr. Rev. 22:565-604
55. Maritzen T, Keating DJ, Neagoe I, Zdebik AA, Jentsch TJ. 2008. Role of the vesicular chloride transporter ClC-3 in neuroendocrine tissue. J. Neurosci. 28:10587-98
56. ATP-channel modulation. J. Physiol. 545:501-7
57. Smith PA, Sakura H, Coles B, Gummerson N, Proks P, Ashcroft FM. 1997. Electrogenic arginine transport mediates stimulus-secretion coupling in mouse pancreatic β-cells. J. Physiol. 499(Pt. 3):625-35
58. Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, et al. 2005. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 54:727-35
59. Ashcroft F, Rorsman P. 2004. Type 2 diabetes mellitus: not quite exciting enough? Hum. Mol. Genet. 13:R21-31
60. + channel in mouse pancreatic β cells. Nature 349:77-79
61. Kailey B, van de Bunt M, Cheley S, Johnson PR, MacDonald PE, et al. 2012. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β3-and tx-cells. Am. J. Physiol. Endocrinol. Metab. 303:E1107-16
62. Walsh KB. 2011. Targeting GIRK channels for the development of new therapeutic agents. Front Pharmacol. 2:64
63. Tirone TA, Norman MA, Moldovan S, DeMayo FJ, Wang XP, Brunicardi FC. 2003. Pancreatic somatostatin inhibits insulin secretion via SSTR-5 in the isolated perfused mouse pancreas model. Pancreas 26:e67-73
64. Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, et al. 2003. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol. Endocrinol. 17:93-106
65. Brunicardi FC, Atiya A, Moldovan S, Lee TC, Fagan SP, et al. 2003. Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas. Pancreas 27:e84-89
66. Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, et al. 2007. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J. Clin. Endocrinol. Metab. 92:673-80
67. Renstrom E, Ding WG, Bokvist K, Rorsman P. 1996. Neurotransmitter-induced inhibition of exocytosis in insulin-secreting β3 cells by activation of calcineurin. Neuron 17:513-22
68. Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, et al. 2012. Reduced insulin exocytosis in human pancreatic β3-cells with gene variants linked to type 2 diabetes. Diabetes 61:1726-33
69. Swayne LA, Mezghrani A, Varrault A, Chemin J, Bertrand G, et al. 2009. The NALCNion channel is activated by M3 receptors in a pancreatic β3-cell line. EMBO Rep. 10:873-80
70. Rodriguez-Diaz R, Dando R, Jacques-Silva MC, Fachado A, Molina J, et al. 2011. ex Cells secrete acetylcholine as a non-neuronal paracrine signal priming β3 cell function in humans. Nat. Med. 17:888-92
71. Galvanovskis J, Braun M, Rorsman P. 2011. Exocytosis from pancreatic β3-cells: mathematical modelling of the exit of low-molecular-weight granule content. Interface Focus 1:143-52
72. Obermuller S, Lindqvist A, Karanauskaite J, Galvanovskis J, Rorsman P, Barg S. 2005. Selective nucleotide-release from dense-core granules in insulin-secreting cells. J. Cell Sci. 118:4271-82
73. Silva AM, Rodrigues RJ, Tome AR, Cunha RA, Misler S, et al. 2008. Electrophysiological and immuno-cytochemical evidence for P2X purinergic receptors in pancreatic β3 cells. Pancreas 36:279-83
74. Fernandez-Alvarez J, Hillaire-Buys D, Loubatieres-Mariani MM, Gomis R, Petit P. 2001. P2 receptor agonists stimulate insulin release from human pancreatic islets. Pancreas 22:69-71
75. Jacques-Silva MC, Correa-Medina M, Cabrera O, Rodriguez-Diaz R, Makeeva N, et al. 2010. ATP-gated P2X3 receptors constitute a positive autocrine signal for insulin release in the human pancreatic β3 cell. Proc. Natl. Acad. Sci. USA 107:6465-70
76. Braun M, Ramracheya R, Rorsman P. 2012. Autocrine regulation of insulin secretion. Diabetes Obes. Metab. 14(Suppl. 3):143-51
77. Okada Y, Taniguchi H, Schimada C. 1976. High concentration of GABA and high glutamate decarboxylase activity in rat pancreatic islets and human insulinoma. Science 194:620-22
78. Wang C, Ling Z, Pipeleers D. 2005. Comparison of cellular and medium insulin and GABA content as markers for living β3-cells. Am. J. Physiol. Endocrinol. Metab. 288:E307-13
79. Braun M, Ramracheya R, Bengtsson M, Clark A, Walker JN, et al. 2010. y-Aminobutyric acid (GABA) is an autocrine excitatory transmitter in human pancreatic β3-cells. Diabetes 59:1694-701
80. Taneera J, Jin Z, Jin Y, Sarheed JM, Zhang E, et al. 2012. The GABA signaling in human pancreatic islets is altered in type 2 diabetes. Diabetologia 55: 1985-94
81. Holst JJ. 2007. The physiology of glucagon-like peptide 1. Physiol. Rev. 87:1409-39
82. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P. 1998. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic β3-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47:57-65
83. Braun M, Ramracheya R, Johnson PR, Rorsman P. 2009. Exocytotic properties of human pancreatic β3-cells. Ann. N Y. Acad. Sci. 1152:187-93
84. Eliasson L, Ma X, Renstrom E, Barg S, Berggren PO, et al. 2003. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic β3-cells. J. Gen. Physiol. 121:181-97
85. /-O-Me-cAMP-AM in human islets of Langerhans. Am. J. Physiol. Endocrinol. Metab. 298:E622-33
86. Scheen AJ, Castillo MJ, Lefebvre PJ. 1996. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab. 22:397-406
87. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, et al. 2003. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52:2461-74
88. Rorsman P, Renstrom E. 2003. Insulin granule dynamics in pancreatic β3 cells. Diabetologia 46:1029-45
89. Hellman B. 1959. Actual distribution of the number and volume of the islets of Langerhans in different size classes in non-diabetic humans of varying ages. Nature 184(Suppl. 19):1498-99
90. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, et al. 1988. Islet amyloid, increased tx-cells, reduced β3-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. 9:151-59
91. Michael DJ, Xiong W, Geng X, Drain P, Chow RH. 2007. Human insulin vesicle dynamics during pulsatile secretion. Diabetes 56:1277-88
92. Ostenson CG, Gaisano H, Sheu L, Tibell A, Bartfai T. 2006. Impaired gene and protein expression of exocytotic soluble N-ethylmaleimide attachment protein receptor complex proteins in pancreatic islets of type 2 diabetic patients. Diabetes 55:435-40
93. +-induced glucagon exocytosis in pancreas. J. Physiol. 587:1169-78
94. Dai XQ, Plummer G, Casimir M, Kang Y, Hajmrle C, et al. 2011. SUMOylation regulates insulin exocytosis downstream of secretory granule docking in rodents and humans. Diabetes 60:838-47
95. Johnson RD, Oliver PL, Davies KE. 2008. SNARE proteins and schizophrenia: linking synaptic and neurodevelopmental hypotheses. Acta Biochim. Pol. 55:619-28
96. Jeans AF, Oliver PL, Johnson R, Capogna M, Vikman J, et al. 2007. A dominant mutation in Snap25 causes impaired vesicle trafficking, sensorimotor gating, and ataxia in the blind-drunk mouse. Proc. Natl. Acad. Sci. USA 104:2431-36
97. Gough SC, O'Donovan MC. 2005. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J. Psychopharmacol. 19:47-55
98. Hanna ST, Pigeau GM, Galvanovskis J, Clark A, Rorsman P, MacDonald PE. 2009. Kiss-and-run exocytosis and fusion pores of secretory vesicles in human β3-cells. Pflug. Arch. 457:1343-50
99. Gopel S, Zhang Q, Eliasson L, Ma XS, Galvanovskis J, et al. 2004. Capacitance measurements of exocytosis in mouse pancreatic ex-, β3-and 6-cells within intact islets of Langerhans. J. Physiol. 556:711-26
100. Seino S, Shibasaki T, Minami K. 2011. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J. Clin. Investig. 121:2118-25
101. Lang DA, Matthews DR, Peto J, Turner RC. 1979. Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N. Engl. J. Med. 301:1023-27
102. Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC. 1989. Similar reduction of first-and second-phase β3-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 38:767-72
103. Varadi A, Tsuboi T, Johnson-Cadwell LI, Allan VJ, Rutter GA. 2003. Kinesin I and cytoplasmic dynein orchestrate glucose-stimulated insulin-containing vesicle movements in clonal MIN6 β3-cells. Biochem. Biophys. Res. Commun. 311:272-82
104. Henquin JC. 2000. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751-60
105. Ivarsson R, Quintens R, Dejonghe S, Tsukamoto K, in't Veld P, et al. 2005. Redox control of exocytosis: regulatory role ofNADPH, thioredoxin, and glutaredoxin. Diabetes 54:2132-42
106. Maechler P, Wollheim CB. 1999. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature 402:685-89
107. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. 2003. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-10
108. Deng S, Vatamaniuk M, Huang X, Doliba N, Lian MM, et al. 2004. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53:624-32
109. McCarthy MI. 2010. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med. 363:2339-50
110. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. 2010. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 42:579-89
111. Bonnefond A, Froguel P, Vaxillaire M. 2010. The emerging genetics of type 2 diabetes. Trends Mol. Med. 16:407-16
112. Eliasson L, Renstrom E, Ammala C, Berggren PO, Bertorello AM, et al. 1996. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic βcells. Science 271:813-15
113. McCarthy MI. 2008. Casting a wider net for diabetes susceptibility genes. Nat. Genet. 40:1039-40
114. Boden G. 2011. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes. 18:139-43
115. Bergman RN, Phillips LS, Cobelli C. 1981. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J. Clin. Investig. 68:1456-67
116. Sako Y, Grill VE. 1990. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and βcell oxidation through a process likely coupledtofatty acid oxidation. Endocrinology 127:1580-89
117. 2+ channels from secretory granules. Cell Metab. 10:455-65
118. Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, et al. 1997. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J. Clin. Investig. 100:398-403
119. Fernandez J, Valdeolmillos M. 1998. Increased levels of free fatty acids in fasted mice stimulate in vivo β-cell electrical activity. Diabetes 47:1707-12
120. Bickerton AS, Roberts R, Fielding BA, Tornqvist H, Blaak EE, et al. 2008. Adipose tissue fatty acid metabolism in insulin-resistant men. Diabetologia 51:1466-74
121. 2+-signaling in pancreatic β-cells. Mol. Cell. Endocrinol. 212:1-9
122. Olofsson CS, Salehi A, Gopel SO, Holm C, Rorsman P. 2004. Palmitate stimulation of glucagon secretion in mouse pancreatic α-cells results from activation of L-type calcium channels and elevation of cytoplasmic calcium. Diabetes 53:2836-43
123. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, et al. 2003. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature 422:173-76
124. Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B. 2003. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 301:406-10
125. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. 2012. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J. Pharmacol. Exp. Ther. 340:483-89
126. McGarry JD. 2002. Banting Lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7-18
127. Stefanovski D, Richey JM, Woolcott O, Lottati M, Zheng D, et al. 2011. Consistency of the disposition index in the face of diet induced insulin resistance: potential role of FFA. PLoS ONE 6:e18134
128. Ashcroft FM. 2010. New uses for old drugs: neonatal diabetes and sulphonylureas. Cell Metab. 11:179-81
129. Unger RH, Cherrington AD. 2012. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Investig. 122:4-12
130. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. 2011. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60:391-97
131. ATP-channels and glucose-regulated glucagon secretion. Trends Endocrinol. Metab. 19:277-84